Journal:

Article Title: Bugging the bugs

doi: 10.1038/sj.embor.embor817

Figure Lengend Snippet: Genomes of human pathogenic bacteria for which sequencing is in progress, but which are not yet published

Article Snippet: Staphylococcus epidermidis (strain ATCC 12228) , 2.4 , Chinese National Human Genome Center, Shanghai; Shanghai Medical University , – , 2003.

Techniques: Bacteria, Sequencing

Journal: BMC Microbiology

Article Title: Real-time quantitative PCR assay development and application for assessment of agricultural surface water and various fecal matter for prevalence of Aliarcobacter faecis and Aliarcobacter lanthieri

doi: 10.1186/s12866-020-01826-3

Figure Lengend Snippet: List of reference strains of target and other bacterial species and strains used in this study

Article Snippet: 66 , S. epidermidis , Clinical isolate , ATCC 12228.

Techniques: Infection

Journal: Experimental and Therapeutic Medicine

Article Title: Effects of mevalonate kinase interference on cell differentiation, apoptosis, prenylation and geranylgeranylation of human keratinocytes are attenuated by farnesyl pyrophosphate or geranylgeranyl pyrophosphate

doi: 10.3892/etm.2020.8569

Figure Lengend Snippet: The mRNA and protein expression of keratin 1 and involucrin following the interference and overexpression of MVK. (A) The mRNA expression of keratin 1 and involucrin. (B) The protein expression of keratin 1 and involucirn. Relative mRNA and protein expression of keratin 1 and involucrin were detected by RT-qPCR and western blotting, respectively. Compared with the negative control group, the mRNA and protein expression of keratin 1 and involucrin were significantly decreased following interference of MVK expression. The decrease in expression of keratin 1 and involucrin following MVK interference was notably attenuated by FPP. Data presented as mean ± SD, n=3/group. ** P<0.01 and *** P<0.001 vs. negative control group. ## P<0.01 and ### P<0.001 vs. MVK interference group. KRT1, keratin 1; IVL, involucrin; MVK, mevalonate kinase; RT-qPCR, reverse transcription-quantitative PCR; FPP, farnesyl pyrophosphate.

Article Snippet: The membranes were blocked at room temperature with 5% non-fat milk for 1 h, and incubated with primary antibodies against MVK (1:1,000; cat. no. 12228-1-AP; ProteinTech Group, Inc.), cytokeratin 1 (1:1,000; cat. no. 16848-1-AP; ProteinTech Group, Inc.), involucrin (1:1,000; cat. no. 55328-1-AP; ProteinTech Group, Inc.), lamin A (1:1,000; cat. no. 10298-1-AP; ProteinTech Group, Inc.), HRAS (1:1,000; cat. no. 18295-1-AP; ProteinTech Group, Inc.), Rho E (1:1,000; cat. no. D223036; Sangon Biotech Co., Ltd.), Rho B (1:1,000; cat. no. 14326-1-AP; ProteinTech Group, Inc.), Rho A (1:1,000; cat. no. 10749-1-AP; ProteinTech Group, Inc.), RAC1 (1:1,000; cat. no. 24072-1-AP; ProteinTech Group, Inc.) and CDC42 (1:1,000; cat. no. 10155-1-AP; ProteinTech Group, Inc.) at 4 ̊C overnight, respectively.

Techniques: Expressing, Over Expression, Quantitative RT-PCR, Western Blot, Negative Control, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Comprehensive Compositional Analysis of the Slit Lamp Bacteriota

doi: 10.3389/fcimb.2021.745653

Figure Lengend Snippet: Bar chart of relative abundances of ASVs classified on genus level. Taxa with relative abundance of less than 1% were collectively summarized as ‘Other’. (A) Taxonomic composition of the slit lamp bacteriota from TC1 (Tertiary Center) and TC2 respectively and the respective sample sites (contact area – TC1: n = 28; ocular – TC1: n = 28; contact area - TC2: n = 14; ocular – TC2: n = 13). (B) Composition of mock taxa and controls (expected = expected mock abundances; mock = mock standard using Bact-0341f/Bact-0785r primers; blank = blank negative control).

Article Snippet: The mock community consisted of 6 typical skin bacterial species in equal total cell abundances ( Acinetobacter johnstonii ATCC 17090, Corynebacterium striatum ATCC 6940, Micrococcus luteus ATCC 4698, Cutibacterium acnes ATCC 11828, Staphylococcus epidermidis ATCC 12228 and Streptococcus mitis ATCC 49456, 16.7% each).

Techniques: Negative Control

Journal: Pharmaceutics

Article Title: Ruthenium Complexes in the Fight against Pathogenic Microorganisms. An Extensive Review

doi: 10.3390/pharmaceutics13060874

Figure Lengend Snippet: Activities of selected ruthenium complexes against bacteria, toxicity to healthy mammalian cells, and mode of action.

Article Snippet: RuNN [ ] , S. aureus ATCC 25,923: 15.6, S. aureus ATCC 700,698 (MRSA): 62.5 S. epidermidis ATCC 12,228: 31.2, S. epidermidis ATCC 358,983: 62.5 , - , no cytotoxic effect against human erythrocytes , bactericidal; inhibits biofilm formation.

Techniques: Bacteria, Activity Assay, Mutagenesis, Membrane, Irradiation, Binding Assay, Inhibition, Disruption, Activation Assay